作者
Martin Schultz, Line Jee Hartmann Rasmussen, Malene H Andersen, Jakob S Stefansson, Alexander C Falkentoft, Morten Alstrup, Andreas Sandø, Sarah LK Holle, Jeppe Meyer, Peter BS Törnkvist, Thomas Høi-Hansen, Erik Kjøller, Birgitte Nybo Jensen, Morten Lind, Lisbet Ravn, Thomas Kallemose, Theis Lange, Lars Køber, Lars Simon Rasmussen, Jesper Eugen-Olsen, Kasper Karmark Iversen
发表日期
2018/12
期刊
Scandinavian journal of trauma, resuscitation and emergency medicine
卷号
26
页码范围
1-10
出版商
BioMed Central
简介
Background
Risk stratification of patients in the emergency department can be strengthened using prognostic biomarkers, but the impact on patient prognosis is unknown. The aim of the TRIAGE III trial was to investigate whether the introduction of the prognostic and nonspecific biomarker: soluble urokinase plasminogen activator receptor (suPAR) for risk stratification in the emergency department reduces mortality in acutely admitted patients.
Methods
The TRIAGE III trial was a cluster-randomized interventional trial conducted at emergency departments in the Capitol Region of Denmark. Eligible hospitals were required to have an emergency department with an intake of acute medical and surgical patients and no previous access to suPAR measurement. Three emergency departments were randomized; one withdrew shortly after the trial began. The …
学术搜索中的文章
M Schultz, LJH Rasmussen, MH Andersen… - Scandinavian journal of trauma, resuscitation and …, 2018